Back
68· Active
Markets2h 2m ago
The US FDA has issued an Import Alert (IA) 66-40 for drugs manufactured at Dabur India's Silvassa plant following identified deficiencies related to data integrity and maintenance lapses.
Silvassa, Dadra and Nagar Haveli, India
Who
US FDA, Dabur India, Vedanta, Platinum Jasmine A 2018 Trust, Lenskart Solutions, GNG Electronics, Vidhi S. Khandelwal, SBI Funds Management, Sneha Sadhwani, Infinite Derivatives LLP
What
The US FDA has issued an Import Alert (IA) 66-40 for drugs manufactured at Dabur India's Silvassa plant following identified deficiencies related to data integrity and maintenance lapses.
When
Thu, 11 Jun 2026 19:11:47 GMT · 2h 2m ago
Where
Silvassa, Dadra and Nagar Haveli, India ·
Why
The US FDA identified deficiencies related to data integrity and maintenance lapses during an inspection of Dabur India's manufacturing plant at Silvassa.
The Frontline Impact
How this affects you
An import alert from the US FDA can significantly affect a company's ability to sell products in the US market, potentially leading to financial losses and reputational damage. The listing of Vedanta subsidiaries could impact investor perception and market valuation of the parent company.
Story chain
1 event in this threadNo related history yet - this is the origin event.
Verified Sources & Citations
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.